Blog posts in April 2020


DEA eases regulations for federally approved drug derived from cannabis

The DEA notified GW Pharmaceuticals that it no longer considers Epidiolex a controlled substance under the federal Controlled Substance Act. The change is effective immediately. The move means that Epidiolex is still a prescription medication but that doctors who prescribe it do not have to be in the DEA’s drug-monitoring program.

[ Read More ]